TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...
Munich, Germany; Atlanta, Georgia - September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal ...
BrainsWay has achieved a successful turnaround with positive adjusted EBITDA and cash flow in Q3/23. The company offers advanced TMS therapy devices and has numerous patents. There are plenty of ...
Researchers from Aalto University and the University of Wisconsin utilised a TMS-EEG device, which combines transcranial magnetic stimulation and EEG, to examine how the brain activity of people in ...
The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...
TMS offers a safe, non-invasive, and drug-free alternative, with no black box warning and no medication-related side effects. Clinical studies show that approximately 60% of patients achieve remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback